Clinical Trials Logo

Filter by:
NCT ID: NCT02632383 Completed - Clinical trials for Diabetes Mellitus, Type 1

Young With Diabetes Type 1 - Test of an mHealth App

Start date: December 2015
Phase: N/A
Study type: Interventional

A multicenter randomized controlled trial testing the app "Young with Diabetes"

NCT ID: NCT02631681 Completed - Prostatic Neoplasms Clinical Trials

Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy

Start date: August 2014
Phase: N/A
Study type: Interventional

Exercise intervention for men with prostate cancer on androgen deprivation therapy.

NCT ID: NCT02631629 Completed - Clinical trials for Vitamin D Deficiency

Food-based Solutions for Optimal Vitamin D Nutrition and Health

ODIN_FOOD
Start date: November 2015
Phase: N/A
Study type: Interventional

This project aims at proving the efficacy and safety of food based solutions to prevent vitamin D deficiency in high risk populations of Caucasian and South Asian origin living in Denmark.

NCT ID: NCT02630875 Completed - Clinical trials for Pediatric Cholestasis

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus

NCT ID: NCT02630654 Completed - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumors

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs

EXPLAIN
Start date: March 24, 2014
Phase:
Study type: Observational

This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed methodology enabling the evaluation of 92 concomitant cancer biomarkers will provide an interesting approach to solve this question (Lundberg et al 2011).

NCT ID: NCT02629783 Completed - Shoulder Pain Clinical Trials

Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain.

PsychShoP
Start date: March 1, 2016
Phase: N/A
Study type: Interventional

Some patients with shoulder pain have decreased body awareness (BA). To some degree, pain among these patients can be increased due to their lack in BA. Psychomotor therapy is thought to improve BA and thereby increase the effect of traditional therapy, such as physiotherapy and exercises. The aim of this study is therefore to investigate if psychomotor therapy, as a complimenting treatment to physiotherapy, decreases shoulder patients' function deficits and pain reported on PRO's, compared to physiotherapy alone.

NCT ID: NCT02629003 Completed - Healthy Clinical Trials

[11C]Cimbi-36 Dosimetry

Start date: December 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dosimetry for the Positron Emission Tomography (PET) tracer [11C]Cimbi-36 in two different Carbon-11 labelling positions. This information will contribute to determining whether [11C]Cimbi-36 can be optimized by changing the C-11 labelling position.

NCT ID: NCT02627963 Completed - Clinical trials for Carcinoma, Renal Cell

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Start date: May 24, 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC). Participants will be randomized (1:1) to treatment with tivozanib or sorafenib. Participants will be stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category (favorable; intermediate; poor) and prior therapy (two prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI); a prior checkpoint inhibitor [programmed cell death -1 protein (PD-1) or PD-1 ligand (PD1-L) inhibitor] plus a prior VEGFR TKI; a prior VEGFR TKI plus any other systemic agent). All participants will be evaluated for progression free survival, overall survival, objective response rate, and the duration of response as well as safety and tolerability. Pharmacokinetic (PK) analyses are also included in study.

NCT ID: NCT02627274 Completed - Breast Cancer Clinical Trials

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Start date: December 7, 2015
Phase: Phase 1
Study type: Interventional

This first-in-human, open-label, multicenter, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of RO6874281 as a single agent (Part A) or in combination with trastuzumab or cetuximab (Part B or C).

NCT ID: NCT02626728 Completed - Rectal Cancer Clinical Trials

A Prospective Feasibility Study for TAMIS

TAMIS
Start date: September 2015
Phase: N/A
Study type: Observational

Most recently, the Transanal Minimally Invasive Surgery (TAMIS) approach combined with single-port technology has allowed that pelvic surgery can be laparoendocopically performed from both its abdominal and perineal aspects.Previously, a strong negative association between medium- and long-term survival and male gender with narrow pelvis have been reported. TAMIS has a significant potantial for improving the quality of the surgical resection of rectal tumors in men with visceral obesity and narrow pelvis. This group of patients have also a high rate of conversion to open surgery. Focusing on improvement in intraoperative conditions and surgical techniques rather than routine conventional procedures may be the way to go concerning favorable short- and long-term outcomes. The selection of adequate surgical approach to the high-risk patients with visceral obesity and a bulky mesentery may prevent or limit the risk for anastomotic leakage and improve oncologic margin clearence. This is a prospective observational feasability study of the TAMIS-procedure.